Join
Live feed
·
PRReleasevia Quantisnow
Affimed N.V. logo

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
AFMD· Affimed N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AFMD (Affimed N.V.) and more on Quantisnow.